Ines-Regina Buth, MA, CBA (Managing Partner & Co-Founder)

Ines-Regina Buth has been active in the life sciences sector for more than 25 years, primarily at the intersection of science, financing, corporate development and leadership. She has a strong track record advising private and public companies across healthcare and innovative technologies — ranging from early-stage ventures to publicly listed international companies.

Throughout her career, she has worked closely with CEOs, CFOs and leadership teams on corporate positioning, financing processes, transactions and stakeholder engagement, often acting as a trusted advisor in situations where communication and strategic alignment directly influence corporate value. Her experience includes corporate partnerships, licensing transactions, financing rounds, M&A, IPOs and due diligence processes, as well as reputation management, crisis situations and leadership communications. She was actively involved in Schering’s listing on the New York Stock Exchange (NYSE) and Micromet’s reverse merger into a NASDAQ-listed company.

Ines is passionate about translating scientific and strategic complexity into clear narratives and positioning frameworks that enable innovation-driven companies to attract investors, partners, customers and talent. Over the years, she has built a strong international network across executives, investors, advisors, media and key opinion leaders.

Prior to co-founding akampion in 2006, Ines held senior positions in investor relations and corporate communications, including Head of Investor Relations at Micromet AG / Inc. (now Amgen) and Head of Investor Relations at LION bioscience AG. She also held IR/PR roles at global blue-chip companies Schering AG (now Bayer Healthcare) and DaimlerChrysler AG. She started her career in corporate communications at MLP AG and Edelman Public Relations, focusing on corporate and financial communications.

Ines holds a Master’s Degree in Communication Management and North American Studies (Free University of Berlin) and is a Certified Biotechnology Analyst (CBA) from the German Association of Investment Professionals (DVFA). She has also completed certified training in speechwriting at the Akademie für Redenschreiben (Dr. Thilo von Trotha and Minita von Gagern).